Biotech News

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

Salarius Pharmaceuticals (SLRX)Salarius Pharmaceuticals2026-06-25 13:46 ESTCompany update

Access the "What This Means" segment here CAMBRIDGE, Mass. and HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide conjugate therapeutics, today announced that it

Open original release

Related news

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

SLRXSalarius Pharmaceuticals2026-06-25 13:46 EST

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Salarius Pharmaceuticals

Salarius Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

SLRXSalarius Pharmaceuticals2026-06-26 07:16 EST

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

SLRXSalarius Pharmaceuticals2026-06-26 07:16 EST

Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement

SLRXSalarius Pharmaceuticals2026-06-26 07:16 EST

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

SLRXSalarius Pharmaceuticals2026-06-26 07:16 EST

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

SLRXSalarius Pharmaceuticals2026-06-26 07:16 EST

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States